Coexistence HBsAg/HBcAC, Clinical Characterístics & Outcomes - Trial NCT05446532
Access comprehensive clinical trial information for NCT05446532 through Pure Global AI's free database. This phase not specified trial is sponsored by Corporacion Parc Tauli and is currently Recruiting. The study focuses on Hepatitis B. Target enrollment is 120 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Corporacion Parc Tauli
Timeline & Enrollment
N/A
Jun 15, 2022
Dec 31, 2022
Primary Outcome
prevalence concomitant HBsAg and HBsAc markers
Summary
HBV infection is a dynamic process with complex interactions between virus replication and
 the host's immune response. The appearance of anti-HBs after HBV infection generally
 indicates recovery and immunity to HBV1 infection. However, there are several published
 studies that describe the coexistence of the marker of chronic infection (HBsAg +) and the
 marker of functional cure (HBsAc +). There are contradictory studies on whether the
 coexistence of HBsAg/HBsAc implies a different clinical course.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05446532
Non-Device Trial